Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1958 1
1961 1
1963 2
1964 2
1966 2
1967 3
1968 1
1969 2
1971 5
1973 4
1974 1
1975 2
1976 1
1979 3
1981 1
1982 1
1983 1
1984 1
1985 3
1986 1
1987 2
1988 6
1989 3
1990 3
1991 6
1992 2
1993 7
1994 8
1995 4
1996 1
1997 5
1998 3
1999 2
2000 8
2001 5
2002 12
2003 9
2004 9
2005 10
2006 15
2007 17
2008 18
2009 21
2010 21
2011 11
2012 33
2013 19
2014 22
2015 18
2016 29
2017 23
2018 17
2019 25
2020 15
2021 18
2022 24
2023 30
2024 33
2025 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

533 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.
Shitara K, Van Cutsem E, Gümüş M, Lonardi S, de la Fouchardière C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W, Liu B, Fornaro L, Ryu MH, Lee J, Faustino C, Metges JP, Tabernero J, Franke F, Janjigian YY, Souza F, Jukofsky L, Zhao Y, Kamio T, Zaanan A, Pietrantonio F; DESTINY-Gastric04 Trial Investigators. Shitara K, et al. N Engl J Med. 2025 Jul 24;393(4):336-348. doi: 10.1056/NEJMoa2503119. Epub 2025 May 31. N Engl J Med. 2025. PMID: 40454632 Clinical Trial.
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.
Kurosaki T, Chamoto K, Suzuki S, Kanemura H, Mitani S, Tanaka K, Kawakami H, Kishimoto Y, Haku Y, Ito K, Sato T, Suminaka C, Yamaki M, Chiba Y, Yaguchi T, Omori K, Kobayashi T, Nakagawa K, Honjo T, Hayashi H. Kurosaki T, et al. Among authors: mitani s. Front Immunol. 2023 Dec 11;14:1325462. doi: 10.3389/fimmu.2023.1325462. eCollection 2023. Front Immunol. 2023. PMID: 38149256 Free PMC article.
Predicting Skeletal-related Events Using SINS.
Nakanishi K, Hijikata Y, Uchino K, Sugimoto Y, Iba H, Watanabe S, Mitani S. Nakanishi K, et al. Among authors: mitani s. Spine (Phila Pa 1976). 2024 Nov 15;49(22):E367-E371. doi: 10.1097/BRS.0000000000004983. Epub 2024 Mar 13. Spine (Phila Pa 1976). 2024. PMID: 38475677
A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS).
Kodama H, Narita Y, Nakamura M, Takahashi M, Mizukami T, Ando T, Mitani S, Komori A, Hosokawa A, Moriwaki T, Sugiyama K, Taguri M, Orihara S, Kagamu H, Yamaguchi T, Nishikawa H, Muro K. Kodama H, et al. Among authors: mitani s. Future Oncol. 2025 Jun;21(14):1753-1759. doi: 10.1080/14796694.2025.2500918. Epub 2025 May 8. Future Oncol. 2025. PMID: 40336472
Observation of the Anisotropic Magneto-Thomson Effect.
Modak R, Hirai T, Mitani S, Uchida KI. Modak R, et al. Among authors: mitani s. Phys Rev Lett. 2023 Nov 17;131(20):206701. doi: 10.1103/PhysRevLett.131.206701. Phys Rev Lett. 2023. PMID: 38039463
[Postero-lateral spinal fusion].
Mitani S, Fukuzawa G, Honda K. Mitani S, et al. Shujutsu. 1971 Apr;25(4):452-9. Shujutsu. 1971. PMID: 5090168 Japanese. No abstract available.
533 results